Peroxiredoxin 1 expression in active ulcerative colitis mucosa identified by proteome analysis and involvement of thioredoxin based on immunohistochemistry

Horie,Kayo; Mikami,Tetuo; Yoshida,Tsutomu; Sato,Yuichi; Okayasu,Isao

doi:10.3892/ol.2017.7549

Peroxiredoxin 1 expression in active ulcerative colitis mucosa identified by proteome analysis and involvement of thioredoxin based on immunohistochemistry

Authors:
- Kayo Horie
- Tetuo Mikami
- Tsutomu Yoshida
- Yuichi Sato
- Isao Okayasu
View Affiliations

Affiliations: Department of Bioscience and Laboratory Medicine, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036-8564, Japan, Department of Pathology, Toho University School of Medicine, Ota‑ku, Tokyo 143-8540, Japan, Department of Pathology, Kitasato University School of Medicine Sagamihara, Yokohama, Kanagawa 252-0374, Japan, Department of Molecular Diagnostics, Kitasato University School of Allied Health Sciences, Sagamihara, Kanagawa 252-0373, Japan
Published online on: December 8, 2017 https://doi.org/10.3892/ol.2017.7549
Pages: 2364-2372
Copyright: © Horie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ulcerative colitis (UC) is a chronic, relapsing, inflammatory bowel disease, and patients with long‑standing UC are at high risk of developing colorectal cancer as a typical case of the organ‑specific chronic inflammation‑carcinoma sequence. Interactions between epithelial and stromal cells and alterations in a variety of stromal microenvironments have been demonstrated to have important roles in the carcinogenesis of UC‑associated carcinoma. Therefore, the identification of proteins in the inflammatory microenvironment is important not only in the epithelium, however also in the stroma of UC inflammatory foci. To identify proteins associated with UC‑associated carcinoma, the present study used proteomic analysis with two‑dimensional electrophoresis and mass spectrometry. Differentially expressed proteins were assessed between active and inactive UC biopsy specimens. Results were verified by immunohistochemistry. Peroxiredoxin 1 (PRDX1) was among the proteins identified to have increased expression in active compared with inactive UC. Immunohistochemical analysis indicated that the expression of both PRDX1 and thioredoxin (TRX) increased with increasing inflammation grade in epithelial cells in UC mucosal crypts. PRDX1‑positive stromal cells in the lower half of the lamina propria increased along with colitis severity. Furthermore, the expression of both PRDX1 and TRX proteins was increased in UC‑associated neoplastic lesions compared with normal mucosa. A stepwise increase in PRDX1 expression was clear with increasing tumor progression in UC‑associated tumorigenesis. Since PRDX1 and TRX overexpression was a unique characteristic of UC activity and UC‑associated neoplastic lesions, PRDX1 and TRX expression may reflect oxidative stress along with the severity of colitis activity and UC‑associated tumorigenesis in patients with UC.

View Figures

View References

1	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
2	Ohshima H, Tazawa H, Sylla BS and Sawa T: Prevention of human cancer by modulation of chronic inflammatory processes. Mutat Res. 591:110–122. 2005. View Article : Google Scholar : PubMed/NCBI
3	Okayasu I: Development of ulcerative colitis and its associated colorectal neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence. Pathol Int. 62:368–380. 2012. View Article : Google Scholar : PubMed/NCBI
4	Wong NA and Harrison DJ: Colorectal neoplasia in ulcerative colitis-recent advances. Histopathology. 39:221–234. 2001. View Article : Google Scholar : PubMed/NCBI
5	Okayasu I, Hana K, Yoshida T, Mikami T, Kanno J and Fujiwara M: Significant increase of colonic mutated crypts in ulcerative colitis correlatively with duration of illness. Cancer Res. 62:2236–2238. 2002.PubMed/NCBI
6	Rhodes JM and Campbell BJ: Inflammation and colorectal cancer: Ibd-associated and sporadic cancer compared. Trends Mol Med. 8:10–16. 2002. View Article : Google Scholar : PubMed/NCBI
7	Sada M, Igarashi M, Yoshizawa S, Kobayashi K, Katsumata T, Saigenji K, Otani Y, Okayasu I and Mitomi H: Dye spraying and magnifying endoscopy for dysplasia and cancer surveillance in ulcerative colitis. Dis Colon Rectum. 47:1816–1823. 2004. View Article : Google Scholar : PubMed/NCBI
8	Fujii S, Katsumata D and Fujimori T: Limits of diagnosis and molecular markers for early detection of ulcerative colitis-associated colorectal neoplasia. Digestion. 77 Suppl 1:S2–S12. 2008. View Article : Google Scholar
9	Vermeire S, Van Assche G and Rutgeerts P: C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 10:661–665. 2004. View Article : Google Scholar : PubMed/NCBI
10	Sachar DB, Smith H, Chan S, Cohen LB, Lichtiger S and Messer J: Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol. 8:647–650. 1986. View Article : Google Scholar : PubMed/NCBI
11	Gabay C: Interleukin-6 and chronic inflammation. Arthritis Res Ther. 8 Suppl 2:S32006. View Article : Google Scholar : PubMed/NCBI
12	Braegger CP, Nicholls S, Murch SH, Stephens S and MacDonald TT: Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 339:89–91. 1992. View Article : Google Scholar : PubMed/NCBI
13	Song M, Wu K, Ogino S, Fuchs CS, Giovannucci EL and Chan AT: A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer. 108:1891–1898. 2013. View Article : Google Scholar : PubMed/NCBI
14	Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE and Seibold F: Fecal calprotectin correlates more closely with the simple endoscopic score for crohn's disease (SES-CD) than CRP, blood leukocytes and the CDAI. Am J Gastroenterol. 105:162–169. 2010. View Article : Google Scholar : PubMed/NCBI
15	Gisbert JP and McNicholl AG: Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 41:56–66. 2009. View Article : Google Scholar : PubMed/NCBI
16	Lehmann FS, Burri E and Beglinger C: The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 8:23–36. 2015. View Article : Google Scholar : PubMed/NCBI
17	Judd TA, Day AS, Lemberg DA, Turner D and Leach ST: Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol. 26:1493–1499. 2011. View Article : Google Scholar : PubMed/NCBI
18	D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, et al: Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 18:2218–2224. 2012. View Article : Google Scholar : PubMed/NCBI
19	van Rheenen PF, Van de Vijver E and Fidler V: Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis. BMJ. 341:c33692010. View Article : Google Scholar : PubMed/NCBI
20	Okayasu I, Yoshida T, Mikami T, Hana K, Yokozawa M, Araki K, Mitsuhashi J, Kikuchi M, Adachi E and Sada M: Mucosal remodeling in long-standing ulcerative colitis with colorectal neoplasia: Significant alterations of NCAM+ or alpha-SMA+ subepithelial myofibroblasts and interstitial cells. Pathol Int. 59:701–711. 2009. View Article : Google Scholar : PubMed/NCBI
21	Araki K, Mikami T, Yoshida T, Kikuchi M, Sato Y, Oh-Ishi M, Kodera Y, Maeda T and Okayasu I: High expression of hsp47 in ulcerative colitis-associated carcinomas: Proteomic approach. Br J Cancer. 101:492–497. 2009. View Article : Google Scholar : PubMed/NCBI
22	Matts SG: The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 30:393–407. 1961.PubMed/NCBI
23	Nagashio R, Sato Y, Jiang SX, Ryuge S, Kodera Y, Maeda T and Nakajima T: Detection of tumor-specific autoantibodies in sera of patients with lung cancer. Lung Cancer. 62:364–373. 2008. View Article : Google Scholar : PubMed/NCBI
24	Nagashio R, Sato Y, Matsumoto T, Kageyama T, Satoh Y, Ryuge S, Masuda N, Jiang SX and Okayasu I: Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas. Pathol Int. 60:71–77. 2010. View Article : Google Scholar : PubMed/NCBI
25	Yamashita K, Yasuda S, Kuba T, Otani Y, Fujiwara M and Okayasu I: Unique characteristics of rectal carcinoma cell lines derived from invasive carcinomas in ulcerative colitis patients. Cancer Sci. 95:211–217. 2004. View Article : Google Scholar : PubMed/NCBI
26	Tokuyama W, Mikami T, Fujiwara M, Matsui T and Okayasu I: Midkine expression in colorectal tumors: Correlation with ki-67 labeling in sporadic, but not ulcerative colitis-associated ones. Pathol Int. 57:260–267. 2007. View Article : Google Scholar : PubMed/NCBI
27	Rhee SG and Woo HA: Multiple functions of peroxiredoxins: Peroxidases, sensors and regulators of the intracellular messenger H2O2 and protein chaperones. Antioxid Redox Signal. 15:781–794. 2011. View Article : Google Scholar : PubMed/NCBI
28	Karihtala P, Mantyniemi A, Kang SW, Kinnula VL and Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res. 9:3418–3424. 2003.PubMed/NCBI
29	Poynton RA and Hampton MB: Peroxiredoxins as biomarkers of oxidative stress. Biochim Biophys Acta. 1840:906–912. 2014. View Article : Google Scholar : PubMed/NCBI
30	Zhang B, Wang Y and Su Y: Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett. 286:154–160. 2009. View Article : Google Scholar : PubMed/NCBI
31	Cha MK, Suh KH and Kim IH: Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res. 28:932009. View Article : Google Scholar : PubMed/NCBI
32	Zhou J, Shen W, He X, Qian J, Liu S and Yu G: Overexpression of prdx1 in hilar cholangiocarcinoma: A predictor for recurrence and prognosis. Int J Clin Exp Pathol. 8:9863–9874. 2015.PubMed/NCBI
33	Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, Sakata H, Matsushita K and Ochiai T: Tumor suppressor prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep. 18:867–871. 2007.PubMed/NCBI
34	Ambrosone CB: Oxidants and antioxidants in breast cancer. Antioxid Redox Signal. 2:903–917. 2000. View Article : Google Scholar : PubMed/NCBI
35	Ding C, Fan X and Wu G: Peroxiredoxin 1-an antioxidant enzyme in cancer. J Cell Mol Med. 21:193–202. 2017. View Article : Google Scholar : PubMed/NCBI
36	Chu G, Li J, Zhao Y, Liu N, Zhu X, Liu Q, Wei D and Gao C: Identification and verification of prdx1 as an inflammation marker for colorectal cancer progression. Am J Transl Res. 8:842–859. 2016.PubMed/NCBI
37	Liu CH, Kuo SW, Hsu LM, Huang SC, Wang CH, Tsai PR, Chen YS, Jou TS and Ko WJ: Peroxiredoxin 1 induces inflammatory cytokine response and predicts outcome of cardiogenic shock patients necessitating extracorporeal membrane oxygenation: An observational cohort study and translational approach. J Transl Med. 14:1142016. View Article : Google Scholar : PubMed/NCBI
38	Serada S, Fujimoto M, Terabe F, Iijima H, Shinzaki S, Matsuzaki S, Ohkawara T, Nezu R, Nakajima S, Kobayashi T, et al: Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis. 18:2169–2179. 2012. View Article : Google Scholar : PubMed/NCBI
39	Arai Y, Arihiro S, Matsuura T, Kato T, Matsuoka M, Saruta M, Mitsunaga M, Matsuura M, Fujiwara M, Okayasu I, et al: Prostaglandin e-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis. Inflamm Bowel Dis. 20:1208–1216. 2014. View Article : Google Scholar : PubMed/NCBI
40	Arai Y, Matsuura T, Matsuura M, Fujiwara M, Okayasu I, Ito S and Arihiro S: Prostaglandin e-major urinary metabolite as a biomarker for inflammation in ulcerative colitis: Prostaglandins revisited. Digestion. 93:32–39. 2016. View Article : Google Scholar : PubMed/NCBI
41	Hagiwara SI, Okayasu I, Fujiwara M, Matsuura M, Ohnishi H, Ito S, Kishimoto H, Nambu R and Kagimoto S: Prostaglandin e-major urinary metabolite as a biomarker for pediatric ulcerative colitis activity. J Pediatr Gastroenterol Nutr. 64:955–961. 2017. View Article : Google Scholar : PubMed/NCBI
42	Marks PA: Thioredoxin in cancer-role of histone deacetylase inhibitors. Semin Cancer Biol. 16:436–443. 2006. View Article : Google Scholar : PubMed/NCBI
43	Mitsumoto A, Takanezawa Y, Okawa K, Iwamatsu A and Nakagawa Y: Variants of peroxiredoxins expression in response to hydroperoxide stress. Free Radic Biol Med. 30:625–635. 2001. View Article : Google Scholar : PubMed/NCBI